Equities Analysts Set Expectations for DNLI FY2029 Earnings

Key Points

• B. Riley revised its FY2029 earnings per share estimate for Denali Therapeutics from $0.27 to $0.19, while the current consensus is a loss of ($2.71) per share.
• The company's stock saw a slight increase, trading at $14.70, with a market capitalization of $2.15 billion and fluctuating between a 12-month low of $10.57 and a high of $33.33.
• Recent insider sales have taken place, with insiders selling around 501,962 shares in the last three months, indicating a 12.50% ownership by corporate insiders.

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Stock analysts at B. Riley lowered their FY2029 EPS estimates for shares of Denali Therapeutics in a report issued on Wednesday, August 13th. B. Riley analyst M. Mamtani now expects that the company will post earnings of $0.19 per share for the year, down from their prior estimate of $0.27. The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.71) per share.

A number of other equities research analysts have also commented on the stock. Wedbush lowered their price target on shares of Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. William Blair upgraded shares of Denali Therapeutics to a "strong-buy" rating in a report on Thursday, April 24th. Bank of America lowered their price target on shares of Denali Therapeutics from $28.00 to $27.00 and set a "buy" rating for the company in a report on Monday, May 19th. HC Wainwright lowered their price target on shares of Denali Therapeutics from $80.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Finally, Robert W. Baird decreased their price objective on shares of Denali Therapeutics from $30.00 to $29.00 and set an "outperform" rating for the company in a report on Thursday, May 8th. One research analyst has rated the stock with a hold rating, thirteen have issued a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $33.85.

Denali Therapeutics Trading Up 1.7%

NASDAQ:DNLI traded up $0.24 during midday trading on Friday, reaching $14.70. 501,395 shares of the stock traded hands, compared to its average volume of 1,409,008. The company has a fifty day moving average of $14.30 and a 200 day moving average of $15.42. Denali Therapeutics has a 12 month low of $10.57 and a 12 month high of $33.33. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.56 and a current ratio of 10.27. The stock has a market capitalization of $2.15 billion, a P/E ratio of -5.25 and a beta of 1.36.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.72) EPS for the quarter, beating analysts' consensus estimates of ($0.74) by $0.02. During the same quarter in the prior year, the business earned ($0.59) EPS.

Insider Buying and Selling

In related news, insider Alexander O. Schuth sold 2,937 shares of the stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $13.58, for a total value of $39,884.46. Following the completion of the transaction, the insider directly owned 242,346 shares in the company, valued at $3,291,058.68. This trade represents a 1.20% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Carole Ho sold 2,937 shares of the stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $13.58, for a total transaction of $39,884.46. Following the completion of the transaction, the insider owned 217,391 shares of the company's stock, valued at approximately $2,952,169.78. The trade was a 1.33% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 501,962 shares of company stock worth $7,520,799 in the last three months. 12.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Envestnet Asset Management Inc. increased its stake in Denali Therapeutics by 34.5% during the 4th quarter. Envestnet Asset Management Inc. now owns 37,622 shares of the company's stock valued at $767,000 after purchasing an additional 9,643 shares in the last quarter. Raymond James Financial Inc. bought a new stake in Denali Therapeutics during the 4th quarter valued at about $533,000. Sterling Capital Management LLC increased its stake in Denali Therapeutics by 589.9% during the 4th quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock valued at $36,000 after purchasing an additional 1,516 shares in the last quarter. Barclays PLC increased its stake in Denali Therapeutics by 8.7% during the 4th quarter. Barclays PLC now owns 278,067 shares of the company's stock valued at $5,666,000 after purchasing an additional 22,184 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in Denali Therapeutics during the 4th quarter valued at about $328,000. 92.92% of the stock is currently owned by institutional investors.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.